These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tirofiban in unstable coronary disease. Liron M N Engl J Med; 1998 Oct; 339(16):1163-5. PubMed ID: 9776651 [No Abstract] [Full Text] [Related]
3. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103 [TBL] [Abstract][Full Text] [Related]
5. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E; N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424 [TBL] [Abstract][Full Text] [Related]
6. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Huynh T; Theroux P; Snapinn S; Wan Y; Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321 [TBL] [Abstract][Full Text] [Related]
7. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Zhao XQ; Théroux P; Snapinn SM; Sax FL Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731 [TBL] [Abstract][Full Text] [Related]
8. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation; 1998 Jun; 97(24):2386-95. PubMed ID: 9641689 [TBL] [Abstract][Full Text] [Related]
9. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes. Campbell P N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228 [No Abstract] [Full Text] [Related]
10. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104 [TBL] [Abstract][Full Text] [Related]
11. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction. Okmen E; Cakmak M; Tartan Z; Cam N Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426 [TBL] [Abstract][Full Text] [Related]
12. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists]. Araujo R; Agustí A Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849 [No Abstract] [Full Text] [Related]
13. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Fernandez JS; Sadaniantz A Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658 [No Abstract] [Full Text] [Related]
14. The glycoprotein IIb/IIIa platelet receptor blocker tirofiban, but not heparin, counteracts platelet aggregation in unstable angina pectoris. Mattsson E; Martinsson A; Nyqvist O; Rasmanis G; Sylvén C; Karlberg KE Am J Cardiol; 1997 Oct; 80(7):938-40. PubMed ID: 9382012 [TBL] [Abstract][Full Text] [Related]